Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70460 | 0.84 | NOTUM (0.58) | NOTUMNPC1RAB9ASMN1; SMN2CA2 | |
| SCHEMBL70911 | 0.84 | HCAR2 (0.45) | NOTUMNPC1RAB9ASMN1; SMN2CA1 | |
| SCHEMBL2330243 | 0.83 | CA1 (0.57) | NOTUMNPC1RAB9ASMN1; SMN2CA1 | |
| SCHEMBL27911606 | 0.81 | CA1 (0.56) | NOTUMNPC1RAB9ASMN1; SMN2CA1 | |
| SCHEMBL19814723 | 0.81 | NOTUM (0.42) | NOTUMNPC1RAB9ASMN1; SMN2CA1 | |
| SCHEMBL25333885 | 0.81 | NOTUM (0.56) | NOTUMNPC1RAB9ACA1CA2 | |
| SCHEMBL69876 | 0.77 | ESRRA (0.62) | NOTUMNPC1CA1CA2CA4 | |
| SCHEMBL28801446 | 0.75 | ESRRA (0.60) | NOTUMNPC1CA1CA2CA4 | |
| SCHEMBL19814199 | 0.74 | ACKR3 (0.53) | NOTUM | |
| SCHEMBL30413027 | 0.74 | NOTUM (0.37) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | claimed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | claimed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | claimed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3566055-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129403-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| EP-1572647-B1 | SYNTHESIS OF AMINES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | BASF SE (DE) | 2016-09-21 | — | — | EP | disclosed |
| US-8822702-B2 | Synthesis of amines and intermediates for the synthesis thereof | BASF SE (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8710093-B2 | Synthesis of amines and intermediates for the synthesis thereof | BASF SE Ludwigshafen (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-2666772-A1 | Synthesis of amines and intermediates for the synthesis thereof | BASF SE (DE) | 2013-11-27 | — | — | EP | disclosed |
| US-20100087660-A1 | SYNTHESIS OF AMINES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | BASF SE (DE) | 2010-04-08 | — | — | US | disclosed |
| EP-1751104-B1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE MANUFACTURE OF RIZATRIPTAN | RATIOPHARM GMBH (DE) | 2010-03-24 | — | — | EP | disclosed |
| US-7645886-B2 | Synthesis of amines and intermediates for the synthesis thereof | Ciba Specialty Corporation (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | RATIOPHARM GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20060058367-A1 | Synthesis of amines and intermediates for the synthesis thereof | CIBA CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1572647-A2 | SYNTHESIS OF AMINES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | Ciba SC Holding AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056769-A2 | SYNTHESIS OF AMINES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | NOTUM 1306/4885NPC1 356/4885RAB9A 2204/4885 |
| US-20100087660-A1 | SYNTHESIS OF AMINES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | PNMT, HNMT, SMS | NOTUM 537/4885NPC1 3787/4885RAB9A 3336/4885 |
| US-20060058367-A1 | Synthesis of amines and intermediates for the synthesis thereof | PNMT, HNMT, MAOA | NOTUM 438/4885NPC1 3612/4885RAB9A 3270/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | NOTUM 86/4885NPC1 201/4885RAB9A 3858/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | NOTUM 1306/4885NPC1 356/4885RAB9A 2204/4885 |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | HTR7, HRH4, CA7 | NOTUM 1084/4885NPC1 2398/4885RAB9A 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.